Imaging in neurology research II: PET imaging of CNS disorders

Small Animal Imaging: Basics and Practical Guide

Volumn , Issue , 2011, Pages 499-513

  Henriksen, Gjermund ^a   Drzezga, Alexander ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892316316     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-12945-2_33     Document Type: Chapter

References (95)

1. Alafuzoff I (1992) The pathology of dementias: an overview. Acta Neurol Scand Suppl 139:8-15
2. Ametamey SM, Kessler LJ, Honer M et al (2006) Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med 47:698-705
3. Benveniste EN, Nguyen VT, O'Keefe GM (2001) Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem Int 39:381-391
4. Brightman M, Reese T (1969) Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 40:648-677
5. Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175-193
6. Cagnin A, Brooks DJ, Kennedy AM et al (2001) In-vivo measurement of activated microglia in dementia. Lancet 358:461-467
7. Chauveau F, Van Camp N, Dollé F et al (2009) Comparative evaluation of the translocator protein radioligands 11C-DPA- 713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation. J Nucl Med 50:468-476
8. Citron M (2004) Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5:677-685
9. Cunningham VJ, Hume SP, Price GR et al (1991) Compartmental analysis of diprenorphine binding to opiate receptors in the rat in vivo and its comparison with equilibrium data in vitro. J Cereb Blood Flow Metab 11:1-9
10. Curtis MA, Faull RLM, Eriksson PS (2007) The effect of neurodegenerative diseases on the subventricular zone. Nature Rev Neurosci 8:712-723
11. Dalley JW, Fryer TD, Brichard L et al (2007) Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 315:1267-1270
12. Drzezga A (2008) Basic pathologies of neurodegenerative dementias and their relevance for state-of-the-art molecular imaging studies. Eur J Nucl Med Mol Imaging 35(suppl 1):S4-S11
13. Eyal S, Hsiao P, Unadkat JD (2009) Drug interactions at the bloodbrain barrier: fact or fantasy? Pharmacol Ther 123:80-104
14. Games D, Adams D, Alessandrini R et al (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523-527
15. Gonzalez-Scarano F, Baltuch G (1999) Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 22:219-240
16. Gordon HL, MN McGowan E et al (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97-100
17. Gotz J, Ittner LM (2008) Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 9:532-544
18. Grover A, Bennet LZ (2009) Effect of drug transporters on the volume of distribution. AAPS J 11:250-261
19. Gunn RN, Gunn SR, Turkheimer FE et al (2002) Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J Cereb Blood Flow Metab 22:1425-1439
20. Hall H, Wedel I, Halldin C et al (1990) Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes. J Neurochem 55:2048-2057
21. Halldin C, Swahn CG, Farde L et al (1995) Radioligand disposition and metabolism-key information in drug development. In: Comar D (ed) PET for drug development and evaluation. Kluwer, Boston, pp 55-61
22. Han H, Cho CG, Lansbury PT Jr. (1996) Technetium complexes for the quantification of brain amyloid. J Am Chem Soc 118:4506-4507
23. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185
24. Heng MY, Detloff PJ, Albin RL (2008) Rodent genetic models of Huntington disease. Neurobiol Dis 32:1-9
25. Henriksen G, Yousefi BH, Drzezga A et al (2008) Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography. Eur J Nucl Med Mol Imaging 35(suppl 1):S75-S81
26. Hjornevik T, Schoultz BW, Marton J et al (2010) "http://www.ncbi. nlm.nih.gov/pubmed/20662879
27. Spinal long-term potentiation is associated with reduced opioid neurotransmission in the rat brain. Clin Physiol Funct Imaging 30:285-293
28. Holcomb L, Gordon MN, McGowan E et al (1998) "http://www.ncbi.nlm. nih.gov/pubmed/9427614
29. Accelerated Alzheimertype phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97-100
30. Honer M, Brühlmeier M, Missimer J et al (2004) Dynamic imaging of striatal D2 receptors in mice using quad-HIDAC PET. J Nucl Med 45:464-470
31. Honer M, Hengerer B, Blagoev M, Hintermann S et al (2006) Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice. Nucl Med Biol 33:607-614
32. Honer M, Stoffel A, Kessler LJ et al (2007) Radiolabeling and in vitro and in vivo evaluation of [18F]-FE-DABP688 as a PET radioligand for the metabotropic glutamate receptor subtype 5. Nucl Med Biol 34:973-980
33. Hsiao K, Chapman P, Nilsen S et al (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102
34. Huang Y, Bae SA, Zhu Z et al (2005) Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents. J Med Chem 48: 2559-2570
35. Hume SP, Gunn RN, Jones T (1998) Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur J Nucl Med 25:173-176
36. Hume SP, Lingford-Hughes AR, Nataf V et al (2007) "http://www.ncbi. nlm.nih.gov/pubmed/17488881
37. Low sensitivity of the positron emission tomography ligand [11C]diprenorphine to agonist opiates. J Pharmacol Exp Ther 322:661-667
38. Ichise M, Meyer JH, Yonekura Y (2001) An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 42:755-763
39. Innis RB, Cunningham VJ, Delforge J et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539
40. Jakob-Roetne R, Jacobsen H (2009) Alzheimer's disease: from pathology to therapeutic approaches. Angew Chem Int Ed Engl 48:3030-3059
41. Jenner P (2008) Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol 64(suppl 2):S16-S29
42. Kawarabayashi T, Younkin LH, Saido TC et al (2001) Agedependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21:372-381
43. Klunk WE, Debnath ML, Pettegrew JW (1995) Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurbiol Aging 16:541-548
44. Klunk WE, Bacskai BJ, Mathis CA (2002) Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 61:797-805
45. Klunk WE, Lopresti BJ, Ikonomovic MD et al (2005) Binding of the positron emission tomography tracer Pittsburgh compound- B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25:10598-10606
46. Kung MP, Kung HF (2005) Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol 32:673-678
47. Kung HF, Pan S, Kung MP et al (1989) In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D2 dopamine receptor imaging agent. J Nucl Med 30:88-92
48. Kung MP, Hou C, Zhuang ZP et al (2002) IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res 956:202-210
49. Kung MP, Hou C, Zhuang ZP et al (2004) Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur J Nucl Med Mol Imaging 31:1136-1145
50. Laruelle M, Slifstein M, Huang Y (2002) Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 27:287-299
51. Liefaard LC, Ploeger BA, Molthoff CF et al (2009) Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography. Epilepsia 50:88-98
52. Lundquist P, Roman M, Syvänen S et al (2007) Effect on [11C] DASB binding after tranylcypromine-induced increase in serotonin concentration: positron emission tomography studies in monkeys and rats. Synapse 61:440-449
53. Ma Y, Kiesewetter DO, Lang L et al (2003) Determination of [18F]FCWAY, [18F]FP-TZTP, and their metabolites in plasma using rapid and efficient liquid-liquid and solid phase extractions. Nucl Med Biol 30:233-240
54. Ma KH, Huang WS, Kuo YY et al (2009) Validation of 4-[18F]-ADAM as a SERT imaging agent using micro-PET and autoradiography. Neuroimage 45:687-693
55. Maeda J, Ji B, Irie T et al (2007) Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 27:10957-10968
56. Manook A, Henriksen G, Platzer S, Yousefi BH, Huisman M, Voss A, Settles M, Neff F, Busch R, Schoor M, Willuweit A, von der Kammer H, Velden J, Wester HJ, Schwaiger M, Drzezga A. Practicable in vivo microPET imaging of amyloid plaques in a new double transgenic mouse model of Alzheimer's disease (Submitted to PLoS 09-PONE-RA- 08856R1-A)
57. Masliah E, Hansen L, Adame A et al (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129-131
58. Mathis CA, Wang Y, Holt DP et al (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46:2740-2754
59. Mathis CA, Bacskai BJ, Kajdasz ST et al (2002) "http://www.ncbi.nlm. nih.gov/pubmed/11814781
60. A lipophilic thioflavin- T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12:295-298
61. McGowan E, Sanders S, Iwatsubo T et al (1999) Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 6:231-244
62. Moresco RM, Lavazza T, Belloli S et al (2008) Quinolinic acid induced neurodegeneration in the striatum: a combined in vivo and in vitro analysis of receptor changes and microglia activation. Eur J Nucl Med Mol Imaging 35:704-715
63. Neumann M, Sampathu DM, Kwong LK et al (2006) "http:// www.ncbi.nlm.nih.gov/pubmed/17023659
64. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130-133
65. Oddo S, Caccamo A, Shepherd JD et al (2003a) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421
66. Oddo S, Caccamo A, Kitazawa M et al (2003b) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24:1063-1070
67. Pedersen K, Simonsen M, Ostergaard SD et al (2007) Mapping the amphetamine-evoked changes in [11C]raclopride binding in living rat using small animal PET: modulation by MAO-inhibition. Neuroimage 35:38-46
68. Pellegrino D, Cicchetti F, Wang X et al (2007) Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats. J Nucl Med 48:1147-1153
69. Radde R, Duma C, Goedert M et al (2008) The value of incomplete mouse models of Alzheimer's disease. Eur J Nucl Med Mol Imaging 35(suppl 1):S70-S74
70. Reese T, Karnovsky M (1967) Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34:207-217
71. Rockenstein E, Crews L, Masliah E (2007) Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 59: 1093-1102
72. Sadée W, Perry DC, Rosenbaum JS (1982) [3H]diprenorphine receptor binding in vivo and in vitro. Eur J Pharmacol 81:431-440
73. Selkoe DJ (2003) Folding proteins in fatal ways. Nature 426:900-904
74. Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192:106-113
75. Seneca N, Zoghbi SS, Skinbjerg M et al (2008) Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA. Synapse 62:756-763
76. Silverman RB (2004) The organic chemistry of drug design and drug action, p65-66. Elsevier, London
77. Sossi V, Dinelle K, Topping GJ et al (2009) Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J Neurochem 109:85-92
78. Sturchler-Pierrat C, Abramowski D, Duke M et al (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94:13287-13292
79. Styren SD, Hamilton RL, Styren GC et al (2000) X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 48:1223-1232
80. Thal DR, Capetillo-Zarate E, Del Tredici K et al (2006) The development of amyloid b protein deposits in the aged brain. Sci Aging Knowledge Environ 8:re1
81. Tokunaga M, Seneca N, Shin RM et al (2009) Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system. J Neurosci 29:1887-1896
82. Toyama H, Ye D, Ichise M et al (2005) PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32:593-600
83. Venneti S, Lopresti BJ, Wang G et al (2009) PK11195 labels activated microglia in Alzheimer's in vivo in a mouse model using PET. Neurobiol Aging 30:1217-1226
84. Waterhouse RN (2003) "http://www.ncbi.nlm.nih.gov/ pubmed/14667492
85. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 5:376-389
86. Wang JL, Parhi AK, Oya S et al (2008) 2-(2;-((Dimethylamino) methyl)-4;-(3-[18F]fluoropropoxy)-phenylthio)benzenamine for positron emission tomography imaging of serotonin transporters. Nucl Med Biol 35:447-458
87. Wilcock DM, Rojiani A, Rosenthal A et al (2004) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24:6144-6151
88. Willuweit A, Velden J, Godemann R et al (2009). "http://www.ncbi. nlm.nih.gov/pubmed/19936202?itool=EntrezSystem2. PEntrez.Pubmed.Pubmed- ResultsPanel. Pubmed- RVDocSum&ordinalpos=1
89. Early-onset and robust amyloid pathology in a new homozygous mouse model of Alzheimer's disease. PLoS One 4:e7931
90. Wong DF, Pomper MG (2003) "http://www.ncbi.nlm.nih".gov/ pubmed/14667490
91. Predicting the success of a radiopharmaceutical for in vivo imaging of central nervous system neuroreceptor systems. Mol Imaging Biol 5:350-362
92. Yazawa I, Giasson BI, Sasaki R et al (2005) Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45:847-859
93. Zhang W, Oya S, Kung MP et al (2005) F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem 48:5980-5988
94. Zhen W, Han H, Anguiano M et al (1999) Synthesis and amyloid binding properties of rhenium complexes: preliminary progress towards a reagent for SPECT imaging of Alzheimer's disease brain. J Med Chem 42:2805-2815
95. Zhuang ZP, Kung MP, Wilson A et al (2003) Structure-activity relationship of imidazo[1, 2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain. J Med Chem 46:237-243